Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK159
- Development stage
- Unknown
- Lead developer
- Asahi Kasei
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK159 is an investigational bispecific antibody developed by Akeso (also known as Akeso Biopharma or Akesios) for the treatment of solid tumors. While specific target details are often proprietary in early development, AK159 is part of Akeso's extensive pipeline of bispecific antibodies designed to modulate the immune system and tumor microenvironment. It is currently being evaluated in Phase 1/2 clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with advanced or metastatic solid tumors. The drug utilizes Akeso's proprietary Tetrabody technology to achieve high binding affinity and stability.
- Other names
- AK159-Akesios-bispecific antibody-solid tumorsAK-159-Akesios-bispecific antibody-solid tumorsAK 159-Akesios-bispecific antibody-solid tumors
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on AK159.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK159.